Erfan Zare

Dr. Erfan Zare

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Erfan ZareErfan Zare
Erfan Zare
Seyyed Mohammad YaghoubiSeyyed Mohammad Yaghoubi
Seyyed Mohammad Yaghoubi
Maedeh KhoshnazarMaedeh Khoshnazar
Maedeh Khoshnazar
SDSina Jafari Dargahlou
Sina Jafari Dargahlou
JMJanvhi Suresh Machhar
Janvhi Suresh Machhar
BMBehzad Mansoori
Behzad Mansoori
MicroRNAs (miRNAs) are pivotal modulators of tumor progression and immune function. Given the central role of the immune system in recognizing and eliminating malignant cells, understanding how miRNAs influence immune responses has become essential for advancing cancer therapy. This review explores the emerging roles of miRNAs in orchestrating cancer immunology, emphasizing their regulation of tumor immune surveillance, immune equilibrium, immune evasion, and immunometabolism. We further illustrate how specific miRNAs modulate the tumor microenvironment by shaping immune cell phenotypes, cytokine networks, and antigen presentation. Some miRNAs enhance cytotoxic T lymphocyte activity, while others promote immune escape by expanding regulatory T cells and myeloid-derived suppressor cells. miRNAs also regulate immune checkpoints (e.g., PD-L1 and CTLA-4), metabolic reprogramming, and stress responses that collectively influence tumor immunogenicity. Additionally, miRNAs are gaining traction as biomarkers for immune activity and predictors of immunotherapy response. Therapeutically, miRNA mimics and inhibitors can enhance anti-tumor immunity, particularly when combined with advanced delivery platforms or immune checkpoint inhibitors. However, challenges such as delivery specificity, off-target effects, and the context-dependent nature of miRNA activity remain significant barriers to clinical translation. Despite shortcomings, miRNAs represent a class of immune regulators with substantial therapeutic potential. Accelerated progress in miRNA-guided therapies is anticipated through deepening insights into miRNA regulatory networks, coupled with integrative multi-omics and AI-driven analytical frameworks. Altogether, miRNAs are a promising frontier in next-generation cancer immunotherapy and precision oncology.

4 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
Seyyed Mohammad YaghoubiSeyyed Mohammad Yaghoubi
Seyyed Mohammad Yaghoubi
Erfan ZareErfan Zare
Erfan Zare
SDSina Jafari Dargahlou
Sina Jafari Dargahlou
MJMaryam Jafari
Maryam Jafari
MAMahdiye Azimi
Mahdiye Azimi
BMBehzad Mansoori
Behzad Mansoori
Prostate cancer (PCa) is a common malignancy in men worldwide, with incidence projected to rise in the coming years. Traditional screening and diagnostic methods, such as prostate-specific antigen (PSA) testing and biopsy, face limitations in specificity and invasiveness. Circulating microRNAs (miRNAs) have emerged as stable, non-invasive biomarkers obtainable via liquid biopsies (blood, urine, semen) that could transform PCa management. These small regulatory RNAs reflect underlying tumor biology and are detectable at early disease stages, enabling improved early detection when used alongside or in place of PSA. Distinct miRNA expression patterns correlate with tumor aggressiveness. For example, miR-141 and miR-375 are elevated in metastatic cases, whereas let-7 family members and miR-326 are upregulated in aggressive disease, highlighting their prognostic value. Moreover, dynamic changes in reported miRNAs during therapy provide real-time insights into treatment response. In androgen-deprivation therapy (ADT), oncogenic miRNAs, such as miR-21 and miR-125b, increase upon resistance, whereas a decline in tumor-suppressive miRNAs, such as miR-23b/-27b, flags the transition to castration-resistant PCa (CRPC). Similarly, baseline levels of miRNAs (e.g., miR-200b/c, miR-20a) can predict chemotherapy outcomes. Integrating multi-miRNA panels has demonstrated superior accuracy for risk stratification and monitoring, paving the way for personalized treatment. Although promising, clinical implementation of miRNA-based assays requires further validation, standardization of protocols, and large-scale prospective studies. Harnessing circulating miRNAs could usher in a new era of precision oncology for PCa, improving early diagnosis, prognostication, and real-time therapeutic guidance.

29 February 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
VAVahid Asghariazar
Vahid Asghariazar
SMShima Makaremi
Shima Makaremi
Erfan ZareErfan Zare
Erfan Zare
HDHesam Danesh
Hesam Danesh
SMSomaieh Matin
Somaieh Matin
ESElham Safarzadeh
Elham Safarzadeh

10 March 2025 in Scientific Reports
Verified
Journal Article
Open access
VAVahid Asghariazar
Vahid Asghariazar
SMShima Makaremi
Shima Makaremi
NANegin Amani
Negin Amani
Erfan ZareErfan Zare
Erfan Zare
MKMahtab Kadkhodayi
Mahtab Kadkhodayi
ESElham Safarzadeh
Elham Safarzadeh
Growing evidence suggests that dysregulated microRNAs were critical in the development of tumors and the progression number of malignancies. This research aimed to check the effect of microRNA 320a-3p transfection on gastric cancer (GC) cell lines. Following transfection, the efficacy was determined by the RT-PCR method. After that, MTT, scratch assay, DAPI staining, RT-PCR, and flow cytometry were used respectively. The results demonstrated that the viability of GC cells considerably decreased following transfection. Moreover, microRNA 320a-3p transfection significantly suppressed cell migration and induced apoptosis in these cells. We found that transfection of microRNA 320a-3p remarkably decreased PD-L1 gene expression and influenced epithelial-mesenchymal transition (EMT)-related and apoptotic gene expressions. The findings propose that microRNA 320a-3p could decrease cell proliferation and migration and induce apoptosis by increasing TP53 and CASP3 expression levels in GC cells. Notably, microRNA 320a-3p might be a potential target in GC immunotherapy by suppressing the PD-L1 gene expression.

23 August 2024 in Prostaglandins & Other Lipid Mediators
Verified
Journal Article
Closed access
VAVahid Asghariazar
Vahid Asghariazar
AKArash Karimi
Arash Karimi
SAShaghayegh Adeli
Shaghayegh Adeli
MKMahtab Kadkhodayi
Mahtab Kadkhodayi
Erfan ZareErfan Zare
Erfan Zare
MVMehdi Asghari Vostakolaei
Mehdi Asghari Vostakolaei

7 February 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
Erfan ZareErfan Zare
Erfan Zare
SMSeyed MohammadHossein Mostafavi
Seyed MohammadHossein Mostafavi
NNNaeim Norouzi
Naeim Norouzi
ALAmirhossein Larijani
Amirhossein Larijani
SMSeyedeh Mohadese Mosavi Mirkalaie
Seyedeh Mohadese Mosavi Mirkalaie
SASaeid Anvari
Saeid Anvari
Background: The management of head and neck squamous cell carcinoma (HNSCC) presents significant challenges due to the complex anatomy of the region and potential functional impairments caused by conventional treatments. Recent advancements in immunotherapy, particularly CAR-NK cell therapy, provide a possible option by using the innate immune system to target tumor cells. Methods: This review focuses on the therapeutic potential of CAR-NK cell potential for head and neck cancer, covering its mechanisms, challenges, and future directions. Results: CAR-NK cell therapy presents an innovative approach with fewer side effects compared to traditional immunotherapies. Targeting specific receptors such as PD-L1, EGFR, CD44v6, and MUC1 enhances tumor cell elimination while minimizing off-target effects. Pre-clinical and early clinical results are promising, pointing toward a possible role in personalized therapeutic options. Conclusions: CAR-NK cells offer a novel therapeutic avenue for HNSCC by combining targeted cytotoxicity with improved safety profiles. Further research and clinical trials are imperative to optimize this approach, paving the way for advanced, patient-specific treatments.